Screener / SEC EDGAR /CIK 0000882095 /10-K filed Feb 24, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Gilead Sciences GILD

Compare with peers Embed
FY2025 at a glance

Sales up 2.4%, free cash flow down to $9.5B

XBRL, from each 10-K
RevenueStatements
$29.4B from $28.8B in FY2024
FY2016FY2025
Net incomeStatements
$8.5B from $480.0M in FY2024
FY2016FY2025
Free cash flowStatements
$9.5B from $10.3B in FY2024
FY2016FY2025
EPS (diluted)Statements
$6.78 from $0.38 in FY2024
FY2016FY2025
Operating marginStatements
34.0% from 5.8% in FY2024
FY2016FY2025
Total debtStatements
$24.9B from $26.7B in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (42)
EPS (ttm)
-3.13
Sales (ttm)
31.0B
Net income (ttm)
-3.9B
Sales growth
+2.4%
EPS growth
n/m
Sales Q/Q
+6.8%
Free cash flow
13.8B
Gross margin
79.9%
Oper. margin
-7.6%
Net margin
-12.5%
FCF margin
44.5%
R&D / sales
19.7%
Dividend
3.16
Debt/Eq
2.01
Curr. ratio
1.38
Cash
6.4B
Op. cash flow (ttm)
14.5B
EBITDA
10.4B
EBITDA margin
35.3%
Net debt
19.8B
Quick ratio
1.23
Interest cover
9.79
ROIC
22.2%
Payout ratio
46.6%
Tax rate
13.1%
Stock pay / sales
3.0%
Shares out.
1.2B
Shares Y/Y
0.0%
Book / share
10.51
Cash / share
5.19
Sales / share
24.98
Asset turnover
0.60
Inventory turns
3.51
Days sales out.
61
Sales 3Y CAGR
+2.6%
Sales 5Y CAGR
+3.6%
EPS 3Y CAGR
+23.0%
EPS 5Y CAGR
+132%
Employees
17,000
Sales / employee
1.8M

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Changes in the numbers

FY2025 against FY2024

What management wrote about it
  • Operating margin widened to 34.0%
    5.8% to 34.0% · Operating income / revenue · 10-K
Changes in the numbers at every company

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 29.4B -0.4% a year Net income 8.5B -5.0% a year
FY2016 revenue 30.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000882095-19-000006 FY2016 net income 13.5B · NetIncomeLoss, 0000882095-19-000006 30.4B FY2016 FY2017 revenue 26.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000882095-20-000006 FY2017 net income 4.6B · NetIncomeLoss, 0000882095-20-000006 26.1B FY2017 FY2018 revenue 22.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000882095-21-000008 FY2018 net income 5.5B · NetIncomeLoss, 0000882095-21-000008 22.1B FY2018 FY2019 revenue 22.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000882095-22-000007 FY2019 net income 5.4B · NetIncomeLoss, 0000882095-22-000007 22.4B FY2019 FY2020 revenue 24.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000882095-23-000007 FY2020 net income 123.0M · NetIncomeLoss, 0000882095-23-000007 24.7B FY2020 FY2021 revenue 27.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000882095-24-000007 FY2021 net income 6.2B · NetIncomeLoss, 0000882095-24-000007 27.3B FY2021 FY2022 revenue 27.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000882095-25-000006 FY2022 net income 4.6B · NetIncomeLoss, 0000882095-25-000006 27.3B FY2022 FY2023 revenue 27.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000882095-26-000006 FY2023 net income 5.7B · NetIncomeLoss, 0000882095-26-000006 27.1B FY2023 FY2024 revenue 28.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000882095-26-000006 FY2024 net income 480.0M · NetIncomeLoss, 0000882095-26-000006 28.8B FY2024 FY2025 revenue 29.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000882095-26-000006 FY2025 net income 8.5B · NetIncomeLoss, 0000882095-26-000006 29.4B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

From the same starting line, FY2016 to FY2025

Revenue, net income and free cash flow, each set to 100 in FY2016. What happened, from the 10-Ks. Not a forecast.

FY2016 = 100
0 50 100 Revenue: $30.4B in FY2016, $29.4B in FY2025 REVENUE $29.4B · 1.0x Net income: $13.5B in FY2016, $8.5B in FY2025 NET INCOME $8.5B · 0.6x Free cash flow: $16.3B in FY2016, $9.5B in FY2025 FREE CASH FLOW $9.5B · 0.6x FY2016 = 100FY2021FY2025
Revenue 1.0x $30.4B to $29.4B
Net income 0.6x $13.5B to $8.5B
Free cash flow 0.6x $16.3B to $9.5B

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share -5.5% a year FY2015 $11.91 to FY2025 $6.78, 10 years
Book value per share +4.0% a year FY2015 $12.19 to FY2025 $18.09, 10 years
Free cash flow per share -5.7% a year FY2015 $13.48 to FY2025 $7.53, 10 years
0 50 100 150 EPS: $11.91 in FY2015, $6.78 in FY2025 EPS $6.78 · 0.6x Book value / share: $12.19 in FY2015, $18.09 in FY2025 BOOK VALUE / SHARE $18.09 · 1.5x FCF / share: $13.48 in FY2015, $7.53 in FY2025 FCF / SHARE $7.53 · 0.6x FY2015 = 100FY2020FY2025

Each line is set to 100 in FY2015, so a line at 200 has doubled. What was filed, not a forecast. A line is left out when it is not above zero in every year.

Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $6.78$18.09$7.53
Dec 31, 2024 $0.38$15.40$8.21
Dec 31, 2023 $4.50$18.15$5.90
Dec 31, 2022 $3.64$16.83$6.61
Dec 31, 2021 $4.93$16.69$8.56
Dec 31, 2020 $0.10$14.41$5.95
Dec 31, 2019 $4.22$17.64$6.51
Dec 31, 2018 $4.17$16.35$5.72
Dec 31, 2017 $3.51$15.50$8.57
Dec 31, 2016 $9.94$13.91$12.00
Dec 31, 2015 $11.91$12.19$13.48

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $18.3B
  • − All liabilities (total assets less equity) $36.3B
  • = Net current asset value -$18.0B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $22.7B
  • − Goodwill $8.3B
  • − Other intangible assets $17.0B
  • = Tangible book value -$2.6B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result. This company does not tag total liabilities, so total assets less equity is used (it includes any non-controlling interest).

GILD against Health care peers

Among the 60 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+3.7%+11.2%
+2.4%47th of 60 · median +7.1%
Net margin
3.1%16.9%
-12.5%59th of 60 · median 9.6%
Return on equity
6.6%19.6%
-29.6%53rd of 54 · median 13.1%
Free cash flow margin
8.2%21.3%
44.5%1st of 56 · median 15.5%
Debt / equity (less is better)
0.860.39
2.0145th of 49 · median 0.66
GILD and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
GILD Gilead Sciences$31.0B +2.4%79.9%-12.5%-29.6%44.5%2.01
AMGN Amgen$38.9B +10.0%70.9%24.1%65.4%24.6%3.76
MDT Medtronic$37.5B +8.4%65.0%13.9%10.4%16.3%0.56
SYK Stryker Corporation$26.3B +11.2%65.3%13.8%15.4%17.4%0.61
DHR Danaher Corporation$25.6B +2.9%58.6%16.9%8.1%22.4%0.53
BDX Becton Dickinson$22.5B +8.2%46.9%4.2%3.9%14.2%0.69
All 60 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by region

From $27.3B of sales to $6.2B of profit FY2021

  • U.S. $19.3B
  • Europe $4.9B
  • Other International $3.2B
Revenue to Gross profit: $20.7BRevenue to Cost of revenue: $6.6BGross profit to Operating profit: $9.9BGross profit to Operating expenses: $10.8BOperating profit to Net profit: $6.2BOperating profit to Tax & other: $3.7BOperating expenses to R&D: $4.6BOperating expenses to Sales, admin & other: $6.2B Revenue: $27.3B REVENUE $27.3B +11% Y/Y Gross profit: $20.7B · 76% margin GROSS PROFIT $20.7B 76% margin Cost of revenue: $6.6B · 24% of revenue COST OF REVENUE $6.6B 24% of revenue Operating profit: $9.9B · 36% margin OPERATING PROFIT $9.9B 36% margin · +144% Y/Y Operating expenses: $10.8B · 40% of revenue OPERATING EXPENSES $10.8B 40% of revenue Net profit: $6.2B · 23% margin NET PROFIT $6.2B 23% margin · +4961% Y/Y Tax & other: $3.7B · 14% of revenue TAX & OTHER $3.7B 14% of revenue R&D: $4.6B · 17% of revenue R&D $4.6B 17% of revenue Sales, admin & other: $6.2B · 23% of revenue SALES, ADMIN & OTHER $6.2B 23% of revenue

From $27.3B of sales to $4.6B of profit FY2022

Revenue to Gross profit: $21.6BRevenue to Cost of revenue: $5.7BGross profit to Operating profit: $7.3BGross profit to Operating expenses: $14.3BOperating profit to Net profit: $4.6BOperating profit to Tax & other: $2.7BOperating expenses to R&D: $5.0BOperating expenses to Sales, admin & other: $9.3B Revenue: $27.3B REVENUE $27.3B +0% Y/Y Gross profit: $21.6B · 79% margin GROSS PROFIT $21.6B 79% margin Cost of revenue: $5.7B · 21% of revenue COST OF REVENUE $5.7B 21% of revenue Operating profit: $7.3B · 27% margin OPERATING PROFIT $7.3B 27% margin · −26% Y/Y Operating expenses: $14.3B · 52% of revenue OPERATING EXPENSES $14.3B 52% of revenue Net profit: $4.6B · 17% margin NET PROFIT $4.6B 17% margin · −26% Y/Y Tax & other: $2.7B · 10% of revenue TAX & OTHER $2.7B 10% of revenue R&D: $5.0B · 18% of revenue R&D $5.0B 18% of revenue Sales, admin & other: $9.3B · 34% of revenue SALES, ADMIN & OTHER $9.3B 34% of revenue

From $27.1B of sales to $5.7B of profit FY2023

Revenue to Gross profit: $20.6BRevenue to Cost of revenue: $6.5BGross profit to Operating profit: $7.6BGross profit to Operating expenses: $13.0BOperating profit to Net profit: $5.7BOperating profit to Tax & other: $1.9BOperating expenses to R&D: $5.7BOperating expenses to Sales, admin & other: $7.3B Revenue: $27.1B REVENUE $27.1B −1% Y/Y Gross profit: $20.6B · 76% margin GROSS PROFIT $20.6B 76% margin Cost of revenue: $6.5B · 24% of revenue COST OF REVENUE $6.5B 24% of revenue Operating profit: $7.6B · 28% margin OPERATING PROFIT $7.6B 28% margin · +4% Y/Y Operating expenses: $13.0B · 48% of revenue OPERATING EXPENSES $13.0B 48% of revenue Net profit: $5.7B · 21% margin NET PROFIT $5.7B 21% margin · +23% Y/Y Tax & other: $1.9B · 7% of revenue TAX & OTHER $1.9B 7% of revenue R&D: $5.7B · 21% of revenue R&D $5.7B 21% of revenue Sales, admin & other: $7.3B · 27% of revenue SALES, ADMIN & OTHER $7.3B 27% of revenue

From $28.8B of sales to $480.0M of profit FY2024

  • U.S. $20.6B
  • Europe $4.6B
  • Rest of World $3.5B
Revenue to Gross profit: $22.5BRevenue to Cost of revenue: $6.3BGross profit to Operating profit: $1.7BGross profit to Operating expenses: $20.8BOperating profit to Net profit: $480.0MOperating profit to Tax & other: $1.2BOperating expenses to R&D: $5.9BOperating expenses to Sales, admin & other: $14.9B Revenue: $28.8B REVENUE $28.8B +6% Y/Y Gross profit: $22.5B · 78% margin GROSS PROFIT $22.5B 78% margin Cost of revenue: $6.3B · 22% of revenue COST OF REVENUE $6.3B 22% of revenue Operating profit: $1.7B · 6% margin OPERATING PROFIT $1.7B 6% margin · −78% Y/Y Operating expenses: $20.8B · 72% of revenue OPERATING EXPENSES $20.8B 72% of revenue Net profit: $480.0M · 2% margin NET PROFIT $480.0M 2% margin · −92% Y/Y Tax & other: $1.2B · 4% of revenue TAX & OTHER $1.2B 4% of revenue R&D: $5.9B · 21% of revenue R&D $5.9B 21% of revenue Sales, admin & other: $14.9B · 52% of revenue SALES, ADMIN & OTHER $14.9B 52% of revenue

From $29.4B of sales to $8.5B of profit FY2025

  • U.S. $20.9B
  • Europe $5.1B
  • Rest of World $3.5B
Revenue to Gross profit: $23.2BRevenue to Cost of revenue: $6.2BGross profit to Operating profit: $10.0BGross profit to Operating expenses: $13.2BOperating profit to Net profit: $8.5BOperating profit to Tax & other: $1.5BOperating expenses to R&D: $5.8BOperating expenses to Sales, admin & other: $7.4B Revenue: $29.4B REVENUE $29.4B +2% Y/Y Gross profit: $23.2B · 79% margin GROSS PROFIT $23.2B 79% margin Cost of revenue: $6.2B · 21% of revenue COST OF REVENUE $6.2B 21% of revenue Operating profit: $10.0B · 34% margin OPERATING PROFIT $10.0B 34% margin · +503% Y/Y Operating expenses: $13.2B · 45% of revenue OPERATING EXPENSES $13.2B 45% of revenue Net profit: $8.5B · 29% margin NET PROFIT $8.5B 29% margin · +1673% Y/Y Tax & other: $1.5B · 5% of revenue TAX & OTHER $1.5B 5% of revenue R&D: $5.8B · 20% of revenue R&D $5.8B 20% of revenue Sales, admin & other: $7.4B · 25% of revenue SALES, ADMIN & OTHER $7.4B 25% of revenue

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 37.5% FY2020: 0.7% net income ÷ equity
Net margin 28.9% FY2020: 0.5% profit per $ of sales: 8.5B ÷ 29.4B
Asset turnover 0.50× FY2020: 0.36× sales per $ of assets: 29.4B ÷ 59.0B
Leverage 2.60× FY2020: 3.76× assets per $ of equity: 59.0B ÷ 22.7B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -12.5% vs 9.6%
  • Return on equity below 15%
    -29.6%
  • A profit in every one of 10 years
Net margin, FY2016 to FY2025: 44.4% to 28.9%

Balance sheet

  • Interest covered more than 5 times
    Operating income is 9.8× interest expense
  • Debt larger than equity
    Debt / equity 2.01 on the latest balance sheet (peer median 0.66)
  • Current assets cover current liabilities
    Current ratio 1.38
  • Net debt under 3 years of free cash flow
    $19.7B net debt, 1.4 years
Debt / equity at each year end, FY2016 to FY2025: 1.39 to 1.10

Cash and shareholders

  • Free cash flow positive in every one of 10 years
    $9.5B last year
  • Share count down over 5 years
    −0.6%
  • Dividend per share up over 5 years
    $2.72 → $3.16
  • Cash from operations above net income
    $10.0B vs $8.5B
Free cash flow, FY2016 to FY2025: 16.3B to 9.5B

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$- of principal due

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities

Paid in advance $57.0M cash received before delivery, not yet recognized as revenue, Sep 30, 2026 · +1.8% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

GILD's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue29.4B
FY2016: 30.4BFY2017: 26.1BFY2018: 22.1BFY2019: 22.4BFY2020: 24.7BFY2021: 27.3BFY2022: 27.3BFY2023: 27.1BFY2024: 28.8BFY2025: 29.4B FY2017FY2019FY2021FY2023FY2025
Net income8.5B
FY2016: 13.5BFY2017: 4.6BFY2018: 5.5BFY2019: 5.4BFY2020: 123.0MFY2021: 6.2BFY2022: 4.6BFY2023: 5.7BFY2024: 480.0MFY2025: 8.5B FY2017FY2019FY2021FY2023FY2025
Free cash flow9.5B
FY2016: 16.3BFY2017: 11.3BFY2018: 7.5BFY2019: 8.3BFY2020: 7.5BFY2021: 10.8BFY2022: 8.3BFY2023: 7.4BFY2024: 10.3BFY2025: 9.5B FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay8.6B
FY2016: 15.9BFY2017: 10.7BFY2018: 6.6BFY2019: 7.7BFY2020: 6.9BFY2021: 10.2BFY2022: 7.7BFY2023: 6.7BFY2024: 9.5BFY2025: 8.6B FY2017FY2019FY2021FY2023FY2025
EPS (diluted)6.78
FY2016: 9.94FY2017: 3.51FY2018: 4.17FY2019: 4.22FY2020: 0.10FY2021: 4.93FY2022: 3.64FY2023: 4.50FY2024: 0.38FY2025: 6.78 FY2017FY2019FY2021FY2023FY2025
Dividend per share3.16
FY2016: 1.84FY2017: 2.08FY2018: 2.28FY2019: 2.52FY2020: 2.72FY2021: 2.84FY2022: 2.92FY2023: 3.00FY2024: 3.08FY2025: 3.16 FY2017FY2019FY2021FY2023FY2025
Diluted shares1.3B
FY2016: 1.4BFY2017: 1.3BFY2018: 1.3BFY2019: 1.3BFY2020: 1.3BFY2021: 1.3BFY2022: 1.3BFY2023: 1.3BFY2024: 1.3BFY2025: 1.3B FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Total HIV 20.8B70.5% +5.8%
Biktarvy 14.3B48.7% +6.8%
Total Oncology 3.2B11.0% -1.6%
Total Liver Disease 3.2B10.9% +6.5%
Descovy 2.8B9.4% +30.5%
Genvoya 1.5B5.1% -15.0%
Yescarta 1.5B5.1% -4.8%
Intangible asset – Trodelvy 1.4B4.7% +6.2%
Sofosbuvir/Velpatasvir 1.3B4.3% -20.3%
Odefsey 1.2B4.0% -9.4%
Vemlidy 1.1B3.6% +11.6%
Veklury 911.0M3.1% -49.4%
Other Liver Disease 874.0M3.0% +87.2%
Royalty, contract and other revenues 527.0M1.8% +266%
AmBisome 509.0M1.7% -4.5%
Other HIV 500.0M1.7% +15.2%
Symtuza - Revenue share 495.0M1.7% -16.4%
Tecartus 344.0M1.2% -14.6%
Other 290.0M1.0% -18.5%

10-K 0000882095-26-000006, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
U.S. 20.9B70.9% +1.4%
Europe 5.1B17.2% +9.3%
Rest of World 3.5B11.9% -0.7%

10-K 0000882095-26-000006, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue30.4B26.1B22.1B22.4B24.7B27.3B27.3B27.1B28.8B29.4B
Cost of revenue4.3B4.4B4.9B4.7B4.6B6.6B5.7B6.5B6.3B6.2B
R&D5.1B3.7B5.0B9.1B4.9B4.6B5.0B5.7B5.9B5.8B
SG&A3.4B3.9B4.1B4.4B5.2B5.2B5.7B6.1B6.1B5.8B
Operating income17.6B14.1B8.2B4.3B4.1B9.9B7.3B7.6B1.7B10.0B
Interest expense964.0M1.1B1.1B995.0M984.0M1.0B935.0M944.0M977.0M1.0B
Pretax income17.1B13.5B7.8B5.2B1.7B8.3B5.8B6.9B690.0M9.8B
Income tax3.6B8.9B2.3B-204.0M1.6B2.1B1.2B1.2B211.0M1.3B
Net income13.5B4.6B5.5B5.4B123.0M6.2B4.6B5.7B480.0M8.5B
EPS (diluted)9.943.514.174.220.104.933.644.500.386.78
Diluted shares1.4B1.3B1.3B1.3B1.3B1.3B1.3B1.3B1.3B1.3B
Depreciation & amortization177.0M233.0M226.0M255.0M288.0M329.0M323.0M354.0M381.0M370.0M
EBITDA17.8B14.4B8.4B4.5B4.4B10.2B7.7B8.0B2.0B10.4B
Operating margin58.0%54.1%37.1%19.1%16.5%36.3%26.9%28.0%5.8%34.0%
Net margin44.4%17.7%24.7%24.0%0.5%22.8%16.8%20.9%1.7%28.9%
Revenue growth-6.9%-14.1%-15.2%+1.5%+10.0%+10.6%-0.1%-0.6%+6.0%+2.4%
EPS growth-16.5%-64.7%+18.8%+1.2%-97.6%+4830%-26.2%+23.6%-91.6%+1684%

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)380.0M638.0M845.0M636.0M643.0M635.0M637.0M766.0M835.0M894.0M
Stock-based pay / revenue1.3%2.4%3.8%2.8%2.6%2.3%2.3%2.8%2.9%3.0%
Operating lease cash paid---66.0M66.0M123.0M98.0M88.0M141.0M127.0M
Right-of-use assets--500.0M668.0M646.0M542.0M505.0M581.0M515.0M532.0M
Operating lease liabilities--500.0M725.0M715.0M590.0M578.0M671.0M611.0M605.0M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GILD/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.